Search Result

Results for "

Cilastatin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (7) Bacterial (7) Reference Standards (2)
By Research Areas:	Infection (7)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-A0166

*Cilastatin* Maximum Cited Publications 6 Publications Verification MK0791	Bacterial Antibiotic	Infection
Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC₅₀ of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC₅₀ of 178 μM. Cilastatin is an antibacterial adjunct .

HY-A0166A

Cilastatin sodium Maximum Cited Publications 6 Publications Verification MK0791 sodium	Bacterial Antibiotic	Infection
Cilastatin sodium (MK0791 sodium) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC₅₀ of 0.1 μM. Cilastatin sodium inhibits the bacterial metallob-lactamase enzyme CphA with an IC₅₀ of 178 μM. Cilastatin sodium is an antibacterial adjunct .

HY-W561907

*IMipenem and cilastatin* sodium**	Antibiotic Bacterial	Infection
IMipenem and cilastatin sodium is a broad-spectrum Carbapenem Antibiotic combination. Imipenem (HY-B1369A) is a Carbapenem antibiotic. IMipenem demonstrates excellent activity against gram-positive and gram-negative aerobic and anaerobic organisms. Cilastatin (HY-A0166) is a renal Dehydropeptidase inhibitor that inhibits the metabolism of Imipenem by renal brush-border enzymes, thus increasing imipenem concentrations in urine .

HY-A0166S

Cilastatin-15N,d3 MK0791-¹⁵N,d₃	Bacterial Antibiotic	Infection
Cilastatin- ¹⁵N,d₃ is a ¹⁵N-labeled and deuterium labeled Cilastatin. Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC₅₀ of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC₅₀ of 178 μM. Cilastatin is an antibacterial adjunct .

HY-A0166R

Cilastatin (Standard) MK0791 (Standard)	Reference Standards Bacterial Antibiotic	Infection
Cilastatin (Standard) is the analytical standard of Cilastatin. This product is intended for research and analytical applications. Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC₅₀ of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC₅₀ of 178 μM. Cilastatin is an antibacterial adjunct .

HY-A0166AR

Cilastatin sodium (Standard) MK0791 sodium (Standard)	Reference Standards Bacterial Antibiotic	Infection
Cilastatin (sodium) (Standard) is the analytical standard of Cilastatin (sodium). This product is intended for research and analytical applications. Cilastatin sodium (MK0791 sodium) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin sodium inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin sodium is an antibacterial adjunct[1][2][3].

HY-W743988

Cilastatin ammonium salt	Antibiotic Bacterial	Infection
Cilastatin ammonium salt is an antibiotic that is relatively effective against Gram-positive cocci with a half-life of 3-4 h .

Cat. No.	Nombre del producto	Chemical Structure

HY-A0166S

Cilastatin-15N,d3
Cilastatin- ¹⁵N,d₃ is a ¹⁵N-labeled and deuterium labeled Cilastatin. Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC₅₀ of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC₅₀ of 178 μM. Cilastatin is an antibacterial adjunct .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
E-mail *

	Sorry, but the email address you supplied was invalid.